Thank you!

Your quote has been successfully submitted!

For products requiring additional information, our team will contact you within 1 business day

Failed

There was an error submitting your quote. Please try again.

MSE PRO (S)-3-Hydroxypyrrolidine, 98.0% Purity– MSE Supplies LLC

Overstock Sale - Select Products 10% Off on Orders of $500 or More! Promo Code:

SAVING10

Shop Now
Menu
Cart

This product has been added to the cart.

MSE PRO (S)-3-Hydroxypyrrolidine, 98.0% Purity - MSE Supplies LLC

MSE PRO (S)-3-Hydroxypyrrolidine, 98.0% Purity

SKU: CM1351

  • $ 49995

MSE PRO™ (S)-3-Hydroxypyrrolidine, 98.0% Purity

MSE PRO™ (S)-3-Hydroxypyrrolidine is a crucial and multifunctional chiral compound employed in organic synthesis to produce biologically active pharmaceuticals and molecules. Its exceptional stereochemical complexity has made it an integral precursor for a range of pharmaceuticals and natural products. Due to its chiral properties, it is highly valuable in asymmetric synthesis and plays a crucial role in determining the properties and activity of the final product.

MSE Supplies offers various N-heterocyclic drug small molecules. Please contact us for bulk orders.

Technical Specifications:

CAS No. 100243-39-8
Chemical name (S)-3-Hydroxypyrrolidine
Synonym(s)

  • (3S)-pyrrolidin-3-ol

  • (3S)-3-Pyrrolidinol
Molecular formula C4H9NO
Pack size

25 g (CM1351)
Molecular weight 87.12 g/mol
Melting point 15 °C
Density  1.078 g/mL
Purity 98.0%
pKa
 		14.91±0.20 (Predicted)
Appearance Clear light yellow to yellow liquid after melting
Storage  2-8 °C, protected from light


References:

[1] Yi, C. B., She, Z. Y., Cheng, Y. F., & Qu, J. (2018). Redox-neutral α-C–H functionalization of pyrrolidin-3-ol. Organic letters, 20(3), 668-671.

[2] Courcambeck, J., Bihel, F., De Michelis, C., Quéléver, G., & Kraus, J. L. (2001). Design of potential new HIV protease inhibitors: enantioconvergent synthesis of new pyrrolidin-3-ol, and pyrrolidin-3-one peptide conjugates. Journal of the Chemical Society, Perkin Transactions 1, (12), 1421-1430.